Moreover, IHC results showed that cotreatment with SM164 and sunitinib enhanced the expression of cleaved caspase-3, a marker of apoptosis, in tumor tissues, and this effect was attenuated upon RIPK1 knockdown (Figure 7, G and H). Here, CASP3 is linked to neoplasm.